AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2642-973X/136
*Corresponding Author: Denis Larrivee, University of Navarra Medical School, Spain.
Citation: Denis Larrivee, (2025), Major Trends in Nuclear Medicine, a Critical Technology in Research and Treatment of Neurological Disorders, J. Brain and Neurological Disorders, 8(1): DOI:10.31579/2642-973X/136
Copyright: © 2025, Denis Larrivee. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 04 March 2025 | Accepted: 14 March 2025 | Published: 21 March 2025
Keywords: radiopharmaceuticals; PET/MRI; radiogenomics; reporter genes; nanoparticles; antisense oligonucleotides; SPECT/CT; click reactions
Nuclear medicine has established an irreplaceable role in biomedical research and disease management. Its unique capacity to visualize molecular events in vivo as they unfold provides diagnostic clarity into functional performance and the option for precise intervention in therapy. Over the last several decades nuclear medicine has evolved from a functional imaging modality using a handful of radioligands, into a modern specialty with the potential for molecular systems imaging. Driving this evolution has been a growing recognition of the need for a systemic understanding tailored to patient need that can support treatment decisions. Developments in radiochemistry, scanning capabilities, and targeted delivery have dominated the toolkit for imaging and treatment of a wide range of molecular processes and gene expressions in domains once considered ‘undruggable’. Key innovations in technology include multimodal imaging systems like PET/MRI, advanced scintillator materials, and reconstruction free algorithms. Radioprobes and radiopharmaceuticals have also benefitted, both from enhanced radiochemical methodology for under-utilized radioligands and large molecules and from novel methods for cellular tracking and intracellular access. This review will explore the dominant pathways of this evolution and their potential for molecular systems imaging.
Over several decades, nuclear medicine has evolved from a functional imaging modality using a handful of radionuclides into a modern specialty that can be described more accurately as molecular imaging. Innovation in equipment and radiopharmaceuticals has yielded a wide array of advances significantly increasing the number and range of diagnostic and therapeutic applications and propelling clinical management [1-4]. As of 2021, for example, the World Nuclear Association documented more than 40 million procedures conducted each year worldwide, with a frequency in developing countries roughly 1/10 that of developed nations [5].
Underlying its growing clinical use is the ability of nuclear medicine to offer an unparalleled, non-invasive view of unlimited depth into intracellular processes, providing diagnostic clarity into cellular processes affecting functional performance and the option for precise intervention in therapy. Molecular imaging techniques, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), notably provide for the spatiotemporal monitoring of biomarkers associated with key cellular processes in disease and tissue dysfunctions. By directly combining medium and long-range positron or gamma-emitting radionuclides to molecular markers it is possible to assess not only the distribution and concentration of biomarker molecules, but also the performance of the function associated with a given biomarker. In cases, the combination of such radionuclides with short range radioisotopes (alpha- or beta-particle emission) can transform the imaging radioligand into a therapeutic tool, a process termed theranostics [3, 6]
Affecting the growth of nuclear medicine is an increasing recognition of the multi-layered and heterogeneous nature of tissue dysfunctions [6]. Advances in genetic methods, gene sequencing and single cell transcriptomics, for example, clearly show the complexity and interconnectivity of tumor microenvironments and their molecular changes as cancer progresses. Dysfunctional heart conditions and degeneration of brain tissue present cases of even greater complexity [3,7,8]. To adequately assess such complex environments requires continual monitoring directed to a spectrum of processes and conducted optimally over various regions and time [6].
The need to monitor multiple processes has been a chief factor driving the current evolution in scanning technology and radiopharmaceutical procedures. Key to the acquisition of such multisource information is the ability to detect unique biomarkers with adequate spatial and temporal precision in a specific tissue domain of interest. This has placed a focus on the development of radiochemical procedures that can generate probes uniquely associated with and targeted to a specific molecular process of interest together with the scanning technology needed to detect them. Imaging techniques, however, have been traditionally difficult to multiplex and hence incapable of probing large numbers of different biomarkers, posing a major obstacle to assessing multiple processes. While this obstacle has been addressed in part by technologies that measure other radionuclide features [9,10], it has also shifted developmental efforts to technologies that are capable of multi-modal data acquisition, such as hybrid MRI and PET scanners [11,12].
Together, such influences have shaped the advances that are heralding a coming era of molecular systems imaging. These advances have generally proceeded along three pathways: in the evolution of radiochemical probes and pharmaceuticals - from crude tools for assessing physiological function to probes for imaging previously inaccessible molecular processes; in the development of methods for precise cellular delivery and molecular targeting; and in the pursuit of multimodal scanners with increasingly refined spatiotemporal accuracy and computational proficiency (Figure 1).
This review will take up the innovations emerging along each of these routes and their contribution to systemic imaging and therapy.
Figure 1: Major trends in nuclear medicine in the 21st century. Advances in nuclear medicine encompass three complementary pathways: radiochemical procedures for under-utilized radio nuclides and large molecules, targeting methods for delivery of radioligands to specific cells and tissues and to intracellular domains, and advances in imaging technology for multimodal and multiprobe monitoring.
[2] Radiochemistry for Probes and Pharmaceuticals
Early radiopharmaceuticals were dominated chiefly by small molecule radioligands [13]. This focus kept to a general conceptual model that viewed medicinal procedures in terms of accessibility and functionality. Small drugs could be made to ‘fit’ molecular pockets corresponding to binding or active sites of receptors and enzymes, thereby modulating the activity of these key proteins and affecting cellular function. By selectively binding to such site’s radiopharmaceuticals could quantify receptor distribution as well as influence relevant activity and provide for targeted therapy. Under this model, the so-called ‘druggable’ space was thus chiefly extracellular and/or limited to membrane bound extracellular receptors, leaving many other components of cellular processes, notably intracellular molecules, unexamined.
By contrast, many new types of molecular pharmaceuticals have become available in the last two decades, expanding the pharmaceutical repertoire and enabling the penetration of the ‘undruggable’ space. Included in this repertoire are various antibodies, peptides, and RNA molecules such as antisense oligonucleotides that are increasingly used to assess or modulate heretofore unmonitored and unmodulated processes and or molecular species [14,15]. Antisense oligonucleotides, for example, are increasingly used for silencing gene expression.
In contrast to small molecular drugs, these new molecular entities typically require new, i.e., previously unused or underused, radionuclides. Whereas classical approaches for radiolabeling of small molecule, drug candidates employed long lived isotopes, e.g., 14C (t1/2 5,730 yrs) and tritium-3H (t1/2 12.3 yrs), molar activities of these radionuclides were too low for large molecules like peptides, proteins, or antibodies. This resulted in the use of short-lived radionuclides like 11C (t1/2 of 20 minutes) and 18F (t1/2 of 110 minutes), which provided higher activity. Additionally, short lived radionuclides more closely matched biological half-life [13], thereby permitting live tracking of novel molecular species.
Increasingly, metallic radionuclides are being employed for labeling of larger molecules [16]. 68Ga (t1/2 of 68 minutes), for example, is employed for radiolabeling of peptides, since its half-life is even closer to the biological half-life of these molecules than radionuclides like 11C and 18F. For monoclonal antibodies, 89Zr and 64Cu are most often used, while for nucleic acid medicines 99mTc is usually preferred.
Peptides
Introducing a radionuclide such as 68Ga into a specific peptide typically proceeds via bifunctional chelating agents or prosthetic groups [6, 13]. Bifunctional chelators are metal-binding chelators that are first bound to a desired peptide and subsequently complexed with the radioactive metal. Early bifunctional chelators of 68Ga were made from 1,4,7,10-tetraaza- cyclododecane-1,4,7,10-tetraacetic acid, termed DOTA, which had also been developed for use with the radionuclide’s yttrium-90, copper-64/67, and later lutetium-177. Besides their use in diagnostic procedures, they have also been employed in theranostics. The peptide radiotherapeutic Lutathera, for example, is complexed with 68Ga as a diagnostic radionuclide, and subsequently bound to 177Lu, which functions therapeutically [13]. Besides DOTA, new bifunctional chelators have been developed that are amenable to kit labeling, such as NOTA (- 1,4,7-triazacyclononane-N, N′, N ′′-triacetic acid - derivatives and their phosphate analogues) and acyclic (HBED - N, N′-Di(2-hydroxybenzyl) ethyle- nediamine-N, N′-diacetic acid, THP – tris (hydroxypyri- dinone)) chelators.
Due to the low molar activity attained in peptides with 14C, radio iodide is a frequently used alternate radionuclide, which binds to prosthetic groups and yields higher specific activities. Among the iodine isotopes most often used are: 123I (t1/2: 13 h; SPECT), 124I (t1/2: 4 days; PET), 125I (t1/2: 59 days; SPECT, in vitro bioassays), 131I (t1/2: 8 days; SPECT, radiotherapy). Radiolabeling with iodine is usually carried out on tyrosine (Tyr) or histidine (His) residues, where an aromatic Tyr or His proton is replaced by the electrophilic radioiodine (I+). Occasionally, 18F is used to label peptides and small protein-based tracers, due to its appropriate half-life and favorable economics. Because the chemical procedures for labeling are difficult to carry out, however, it is a less frequently used option.
Antibodies and antibody fragments
Various labeling procedures have been used to bind radionuclides to antibodies [17,18]. Among these are radiometals complexed with chelators or binding to prosthetic groups with Iodine, procedures similar to methods used for peptides. In cases, dual labeling with radionuclides and fluorescent probes is reported [3]. For radiolabeling of monoclonal antibodies, 89Zr (t1/2: 78 h) and 64Cu (t1/2: 13 h) (for PET) and 111In (t1/2: 168 h) (for SPECT) are often employed in diagnostic imaging. Tritium labeling is also frequently used to monitor the pharmacokinetic behavior of candidate antibodies preclinically.
Complicating the use of radiolabeled antibodies, however, is a complex pharmacokinetic pattern, which is due to their large size, long circulating half-life, and immunogenic responses. These complications make accurate predictions about the distribution of monoclonal antibodies difficult to achieve [13]. Additionally, candidate antibodies have the potential for generating immunogenic responses, resulting in the production of anti-drug antibodies. Such antibodies, when generated to the candidate antibody drug, reduce the drug’s efficacy and may in cases completely neutralize its intended therapeutic effects. Nonetheless, the ability of radioimmunotherapies to deliver high radiation doses with precision make them attractive therapeutic options.
Oligonucleotides
Oligonucleotides are increasingly used therapeutically to modify intracellular processes or gene products, frequently through gene silencing, but also by gene activation or modulating splicing assembly stages [14,19]. For nucleic acid- based medicines, radiolabeling requires that several factors be considered to optimize signal level and selectivity.
Each of the three isotopes primarily used for radiolabeling of oligonucleotides, 3H, 14C, 35S, present difficulties for imaging [13], which need to be considered in the selection of radio nuclide. For instance, the relatively long terminal elimination half-life of oligonucleotides, in some cases 30–60 days or even longer, poses a significant disadvantage affecting considerations of metabolic stability. Additionally, 14C typically needs to be incorporated in the C2 pyrimidine position to achieve sufficient activity for detection. In the case of tritium, the C-8 position of purines may undergo tritium-hydrogen back-exchange with the resulting formation of tritiated water, especially under alkaline conditions.
Besides long-lived radionuclides, short life span radionuclides have also been used for radiolabeling of oligonucleotide pharmaceuticals. Among these 99mTc (t1/2: 6 h) is the most frequently used radionuclide for diagnostic applications, particularly for applications using SPECT- based imaging. Binding methods for 99mTc employ either bifunctional chelators or prosthetic groups, as with peptides.
Specialized reactions
The development of biorthogonal reactions known as click reactions [13,20-23], which minimally disrupt cellular processes, has enabled the selective, rapid, and relatively straightforward binding of radiolabel to biological compounds. The earliest of these reactions, known as the Staudinger reaction, involved the reaction of an azide with a phosphine. However, its slow reaction kinetics led to the current inverse electron-demand Diels–Alder (IEDDA) ligation between tetrazine (Tz) derivatives and trans-cyclooctene (TCO). Current developments continue to search for an optimal balance between stability and reaction rate, as more rapidly binding reactions are also more prone to decomposition.
[3] Targeting and Delivery
The development of novel methods for precisely targeting drug delivery or selectively monitoring cellular processes have greatly expanded the domain accessible to diagnosis and therapy. Targeted radiopharmaceutical delivery with imaging has thus become a pillar for therapeutic intervention and key to obtaining critical in vivo data on the functional well-being of specific molecular processes altered by disease. In principle, such precision contains the latent possibility for monitoring and treating multiple processes affected by disease and hence of attaining to a systemic and personalized level of care.
Targeting methods can vary widely to accommodate a range of objectives and can include procedures for overcoming physical and chemical barriers, identifying and tracking select cells, accessing and monitoring intracellular processes, and modulating genetic expression, among others.
Overcoming physical barriers
Among the new methods are procedures for accessing specific tissues, which have been shown to successfully surmount physical and/or biochemical barriers to the entry of radiolabeled compounds. For example, a fundamental limit on the use of radioligands in the brain is the blood brain barrier (BBB). Accordingly, radioligands must be designed to incorporate features enabling the ligand to overcome this barrier. For many such compounds this can be achieved by using radioligands of small molecular weight, generally not exceeding 500 daltons. Because many of the new radiopharmaceuticals are larger than this, however, novel procedures are required for the radioligand to bypass the BBB.
Recent developments in nanotechnology, particularly, afford platforms that can cross the BBB and can carry larger molecular weight radioligands [24]. By manipulating the physical and chemical properties of these nanoparticles (NPs), radiopharmaceutical agents can be attached or loaded. For example, organically modified amino- functionalized silica NPs have been used to carry the gene encoding GDNF to striatal cells [24]. Currently, there is a large and growing number of different NP platforms, which have been used to treat such diseases or dysfunctions as pancreatic cancer, diabetic nephropathy, and myocardial infarction [24,25].
Besides nanoparticles, viral vectors are also increasingly used to deliver radioligands. Viral vectors for neurological tissue now include a broad spectrum of vehicles that have been derived from multiple viral classes. Among these are included retrovirus, lentivirus, adenovirus, herpes simplex virus type 1(HSV-1) and AAV vectors, with recombinant adeno-associated virus (rAAV) vectors generally finding more frequent use [26,27]. Recombinant AAV vectors feature numerous advantages. They are nonreplicable, non-pathogenic, and do not integrate into the host genome [14]. Pre-clinical in vivo AAV gene therapy studies, for example, have been carried out for Huntington’s Disease that have utilized both shRNA and miRNA approaches [27].
Cell Specific Identification and Tracking
Radioimmuno-diagnostic or radioimmuno-therapeutic tracers afford the opportunity to pinpoint molecular and cellular species and are typically constructed from monoclonal antibodies and their derivatives. When combined with radionuclides, it is possible to obtain critical information on antigen quantitation, heterogeneity, and kinetics in real time. A wide variety of radionuclides are currently available, including actinium-225 (225Ac), astatine-211 (211At), bismuth-213 (213Bi), indium-111 (111In), iodine-123 (123I), iodine-124 (124I), iodine-131 (131I), lead-212 (212Pb), lutetium-177 (177Lu), technetium-99m (99mTc), copper-64 (64Cu), gallium-68 (68Ga), yttrium-86 (86Y), yttrium-90 (90Y), and zirconium-89 (89Zr). The choice of radionuclide is based on several properties that are dictated by need and objective, which can include emitter type, energetics, and half-life, as well as tissue characteristics. Efficient radiolabeling is often carried out by binding the radionuclide to a bifunctional chelator, which possesses a binding site for the radionuclide and a linker that can attach a nucleophilic group to a carrier antibody [6,13,28].
Targeting extracellular proteins
Extracellular proteins can, in cases, precipitate disease symptoms. For example, much evidence reveals the involvement of mutant huntingtin protein (mHTT) in extracellular events that influence the severity, symptomatology, and propagation of Huntington’s Disease across cell systems. Among the various mechanisms proposed for influencing these features are effects on brain related immunogenicity, a seeding pathology that amplifies mHTT mobilization, and prion like activity [12]. The extracellular antibody targeting of these aspects has the advantage of requiring simpler protocols than those needed for cell entry, such as directly exposing the immune system to the mutant form of HTT, which makes it a desirable protocol objective.
Targeting free/extracellular mHTT can be carried out by passive or active immunization. In active immunization the immune system is exposed to an exogenous antigen to elicit an adaptive immune response. This process has the advantage of generating an acquired immune response that is relatively long lasting. In passive immunization exogenous antibodies are introduced to suppress antigenicity. While passive immunization generates a relatively rapid response, the introduction of exogenous antibodies lasts for a much shorter interval than active immunization.
In vivo cell tracking using direct cell labeling
Radioligand imaging using single photon emission computed tomography (SPECT) or positron emission tomography (PET) has several advantages over other imaging modalities for cell tracking because of its high sensitivity and whole-body quantitative imaging capability with clinically available scanners. For cell tracking, ex vivo direct cell radiolabeling, that is, radiolabeling cells before their administration, is the simplest and most robust method, allowing labeling of any cell type without the need for genetic modification [29].
Cells are usually radiolabeled ex vivo by incubation with a radiotracer, followed by injection of the radiolabeled cells into the imaging subject. In vivo PET or SPECT imaging can then be performed over time to assess the distribution of the cells. The radiolabeling mechanism can vary depending on the type of probe. Cells can either be radiolabeled using radiotracers designed to bind to the cell membrane or specifically designed to penetrate the membrane where they become trapped intracellularly. A limitation of direct cell labeling is that the imaging time window of this technique is restricted by the half-life of the radionuclide used, with progressive loss of signal strength. Direct cell labeling can also be affected by the efflux of the radiotracer from the radiolabeled cells in vivo. Hence, ideal, direct cell labeling agents should facilitate fast, efficient (high yield) cellular uptake, with high cellular retention of the radionuclide, while not affecting cell viability. Furthermore, they should allow imaging over relatively long periods of time if needed for a given imaging application. Accordingly, long-lived radionuclides (such as 111In, 89Zr) are usually preferred.
Most compounds used for direct cell radiolabeling are “radiometal−ionophore” complexes, which consist of a radio- metal and an ionophore, a ligand which binds to a metal ion reversibly for transport across lipid membranes [30] The resulting radiometal complex is sufficiently hydrophobic to allow passage across cell membranes but insufficiently stable to remain intact within the cell. Once inside the cell, the radiometal can be captured by intracellular proteins or other macromolecules [31] resulting in trapping of the radionuclide−and generation of a radiolabeled cell. Despite the successful use of ionophore ligands for transport of label into cells, the potential radiotoxicity associated with delivery of ionizing radiation intracellularly can pose a danger to cell health and viability. One approach to mitigating this danger is by radiolabeling cells on the cell membrane, further away from the nucleus, with the prospect of reducing Auger-electron toxicity originating from some nuclides.
Accessing and monitoring intracellular processes
Reporter genes
A key question has been that of which sets of protein interactions mediate particular cellular processes and how these become dysfunctional in disease. Increasingly, reporter gene imaging has been used for introducing radiolabeled imaging agents into cells to assay the activity of specific cell processes. When introduced into target cells, reporter genes produce a protein receptor or enzyme that binds, transports, or traps a subsequently injected imaging radioprobe, which becomes the contrast agent [29,32]. Currently, recombinant adeno-associated viral (AAV) vectors are the most frequently used delivery method for effective cell transduction and stable expression of a modified gene.
Several gamma-emitting radionuclides are available for radiolabeling injected agents, ranging from small molecules and peptides to antibodies, nanoparticles, and cells. In the clinic, the most widely used radionuclide is 99mTc, which has a moderately short half-life (6 hours). This is long enough for convenient synthesis of radiotracers (while not imposing prolonged radiation exposure to the subject), offers favorable emission properties, and has convenient production methods. Because of its metallic character, 99mTc radiotracers employ coordination complexes to bind the radionuclide with a chelating agent [6,13].
Despite significant limitations initially with the biodistribution and specificity of reporter gene products, there is a growing repertoire of available reporter genes that could be used for tracking cellular processes and protein-protein interactions within them. Following the advent of standardized genetic editing techniques, researchers have isolated a large collection of reporter and modifier proteins (RPs and MPs, respectively) from a variety of species that have since been instrumental in characterizing a wide range of biological processes [32]. For example, RPs are frequently used to tag endogenous proteins or to track the behavior of individual cells in vivo.
Antibody fragments
An especially promising avenue employs radiolabeled antibody fragments as reporter probes [32,33]. Antibody fragments retain the ability to target specific protein domains that may be critical in mediating protein-protein interactions and are more accessible to restricted sites than whole antibodies due to their smaller size. Their mode of action is to suppress protein activity by directly binding to functional domains, thereby interfering with the ability of aberrant proteins to interact with binding partners; or to redirect the pathogenic protein to clearance processes.
Research with intrabodies has been conducted for several decades. The first intrabodies for functional sites on huntingtin protein, for example, were generated from a human spleen, single- chain variable fragment (scFv) phage library [34]
Modulating genetic expression
Nucleic acid therapies for chronic diseases typically adopt one of two approaches, interference with protein specific, RNA translation mechanisms or direct modification of the genes of protein products. RNAi approaches employ short-interfering RNAs (siRNA) or microRNAs (miRNA) [35]. These molecules target mature mRNA in the cytosol, triggering degradation through the RNA-induced silencing complex and eventually reducing protein expression [36]. Gene therapy, on the other hand, entails the use of altered genes (termed transgenes) to treat and prevent disease [37]. Nucleic acid-based approaches have employed gapmer anti-sense oligonucleotides (ASO) and anti-sense oligonucleotides [14,38]. The former are a string of nucleotides with a central unmodified region flanked by modified nucleotides. Such radiolabeled drug oligonucleotide probes can provide a reliable quantitative tool for distribution, mass balance, and metabolite profiling studies [39].
To induce expression, several cancers and/or tumor-specific promoter’s systems have been developed. Tumor-specific promoters that are over-expressed in the tumor can induce specific therapeutic genes, enhancing their localized activity [40].
[4] Advances in Technology
Despite the current plethora of candidates, imaging procedures for nuclear medicine have proven difficult to multiplex, making the development of scanners capable of imaging molecular systems an ongoing effort. Recent studies into the use of energy resolution for distinguishing radionuclides have achieved only limited success, typically with two or three nuclides. Complicating these efforts are inherent limits on signal resolution, particularly in cases in which the ratio of dose to target object is small and where contamination from other tracers and Compton scattering significantly impact signal resolution [9,10,41].
Accordingly, most innovation in scanning technology to date has occurred in the domain of multimodal instrumentation, where various information modes are combined with that of nuclear imaging, as in hybrid PET and MRI. One outcome of this focus, for example, has been the emergence of radiogenomics [42,43]. In this methodology magnetic resonance spectroscopy (MRS) and PET imaging data are correlated with data from genome sequencing to yield correlation matrices used to guide personalized treatments without the need for pathology specimens.
Besides such multimodal scanners, improved characterization of cellular processes has helped to clarify areas where advances in nuclear medicine technology can assist diagnosis and therapy, including enhanced monitoring of the dynamics and quantitation of radioligand probes and radiopharmaceutical delivery. Among these are improvements in signal acquisition and system sensitivity and stability, as well as computational proficiency.
PET/MRI
Combining PET and MRI into a single device that can acquire both datasets simultaneously has been an objective for several decades [11,12,44,45]. Simultaneous acquisition provides for the temporal correlation of data sets, which, given the dynamic nature of PET measurements, can undergo substantial change during the interval between dataset readings and must be accurately adjusted for in co-registration procedures.
The techniques of PET and MRI provide complementary types of information [11,12]. On the one hand, PET can yield insight into the physiological and metabolic features of patient tissue by tracking the distribution of molecules in vivo using radionuclide positron emission. Because of the nature of the emission, however, spatial resolution is limited, restricting the ability of PET to localize events that radio-tracers are illuminating. MRI, on the other hand, can yield precise anatomical and structural imagery that has superior contrast in soft tissue. The evolution in modern
MRI techniques has additionally exploited other sources of endogenous contrast to monitor function (functional MRI), physiology (diffusion tensor MRI), and composition (magnetic resonance spectroscopy) [46,47], expanding the available repertoire of hybrid instrumentation.
For multimodal imaging, significant changes in instrumental design have been required. A chief obstacle in PET imaging has involved magnetic field interference on the performance of photomultiplier tubes. In early modifications this obstacle was addressed by integrating PET detectors in specialized MRI scanners such as split- magnet or field-cycled units [48,49]. Later and more successful modifications have been achieved with the development of MRI-compatible photon detectors that could be placed inside the magnet’s bore. Avalanche photodiodes, for example, were capable of functioning in the presence of even ultra-high magnetic fields [12] allowing their use with MRI in brain imaging. Solid-state photomultipliers (SSPM), silicon photomultipliers (SiPMs) or multi-photon pixel counters (MPPC)) are now the photon detectors of choice for hybrid units. Most PET systems use lutetium oxyorthosilicate (LSO) or lutetium yttrium oxyorthosilicate (LYSO) as scintillator materials [3]. For MRI imaging, a major hurdle to combined modalities involved the maintenance of magnetic field homogeneity with the placement of PET components inside the MRI scanner bore. To overcome this hurdle only non-magnetic versions of working components are currently used. Additionally, electromagnetic interference in the radiofrequency range is minimized and the shielding designed to avoid currents that occur due to changes in the magnetic field gradient during scanning.
MRI as a structural framework for PET in combined systems
Improved spatiotemporal accuracy of PET estimates has been achieved through the use of MRI data to provide a structural framework on which the simultaneously recorded PET signal is distributed. Combining these with adjunct computational analyses such as time of flight localization and principal components analysis has been shown to further enhance spatial resolution.
Time of flight localization: Time of flight information (TOF) narrows the spatial location of positron emission, thereby improving the spatial resolution of emitted signals by compensating for positron travel time. In principle, time of flight computations rest on the detection of the physical annihilation of the positron and the generation of two 511 kEV photons that are separated by 180 degrees. The computational steps are straightforward and use the following equation:
D1 – D2 = (t1- t2) x c
where c is the speed of light and t1 and t2 are the recorded detection times. Uncertainty in the time measurements is incorporated in computations by use of TOF probability distributions.
Time of flight technology has undergone a significant improvement in localization capability due to the evolution in silicon photomultiplier tubes and the use of scintillators with improved performance [3,4], such as those containing lutetium oxyorthosilicate or lutetium yttrium oxyorthosilicate. With these materials, the current coincidence time resolution is listed at 200 pico-seconds, while experimental systems have been able to achieve nearly double that at 100 pico-seconds. Given ongoing developments, time of flight determinations may eventually prove sufficient for clinical localization, obviating the need for reconstruction algorithms [3,50].
Quantitative evaluation of PET data using MRI
Attenuation correction: Attenuation correction in procedures such as PET/CT scanning can be directly carried out based on photon attenuation in the tissue medium and its conversion via 512 keV linear attenuation coefficients. MRI based attenuation correction in combined PET/MRI, however, is challenging due to MRI datasets that are based on proton density and relaxation rates rather than on electron density. The latter must therefore be inferred to provide for PET attenuation. Accordingly, several methods have been developed to correct for tissue attenuation in PET/MRI [51–53].
One class of methods employs PET emission data to estimate attenuation data via iterative joint estimation, based on maximum likelihood (ML) [51]. Other procedures derive attenuation data from MRI based information. These may use precompiled atlas pairing, which relates MRI and PET images via an algorithm, or direct imaging using Dixon, ultra-short echo (UTE) or zero echo time (ZTE) methods that avoid use of complex imaging registration and processing procedures. In the direct method, individual patient MR images are segmented into several tissue classes with individual tissue classes assigned a constant or continuous attenuation factor value. In the direct 2-point Dixon method [52] two different echo times are used based on the different precession rates of fat and water molecules.
This method, however, does not compensate for lung and bone readings, which thus distorts the attenuation correction. An alternative and frequently employed approach is the use of an ultra-short time echo (UTE) sequence, with acquisition times approximately 100-fold shorter than echo times typically used in T1-weighted MR images [53]. Using these techniques, for example, a recent region of interest analysis of inflammation in Huntington’s Disease with the tracer 11C-PBR28, showed statistically significant differences between manifest patients and controls in the pallidum and putamen regions of the brain [46].
Principle Components: Objective methods for PET typically treat voxels as if they represented independent or uniformly correlated measures throughout the brain, an unwarranted presumption given the brain’s known structural variation. Principal components analysis assists in accounting for this variation, reducing the original dimensionality of imaging data to a suite of low dimensional contributing features. The magnitude of a feature’s contribution to signal variation within a PET image can then be assigned to individual component axes.
In practice, data are typically transformed into a (n x v) data matrix where n is the number of image observations and v is the number of voxels. Principal components and their variance are obtained from the eigenvectors and eigenvalues, respectively, which are determined from the correlation matrix of the data matrix [54]. One of the important features of PCA is to provide quantitative coordinates for the observations on uncorrelated axes. The coordinates are then quantitatively related to attributes of the individuals. In a principal components study of Huntington’s disease subjects, for example, atrophy of the caudate was found to be a significant contributor to the total correlation as a function of the stage of disease progression [46]. The identification of this component - along a first PCA axis - was sufficient to classify HD subjects according to their disease status.
Image-based radiotracer AIF estimation and radiotracer delivery quantitation: Accurate PET quantification requires an input function to compartment models used for estimating parameters of interest for normal and pathologic changes in tissue function or metabolism. For example, a plasma time–activity curve of tracer delivery to the tissue is typically derived from a radiotracer arterial input function (AIF) [12]. Because the determination of the AIF involves radial artery catheterization, however, its use is limited in routine PET studies. Accordingly, noninvasive image-based techniques have been proposed.
One such method is a derivation of the AIF determined from blood vessel, regions of interest, obtained after administering a tracer. Correctly defining the region of interest over a vessel together with confounding effects can be challenging using PET images only, however. This drawback has been addressed and circumvented in a combined scanner, where coregistered and simultaneous MRI anatomic images can be used to accurately measure the position and size of the vessels of interest. With coadministration of both MRI contrast and PET tracers, MRI can also provide information about the dynamics of bolus delivery to the tissue of interest and assess any local changes in blood flow, thereby reducing the effects of bolus delay and dispersion in the AIF estimate [55].
Dynamic acquisition of uptake and elimination of tracer over time additionally allows for kinetic analysis of data sets, which may be clinically relevant. With combined PET/MRI systems, kinetic models can be developed that use both dynamic PET and dynamic MRI data for parameter estimation. These systems also provide for non-invasive estimation of the input function, which is needed for kinetic modelling.
MRI based PET motion correction
Simultaneous PET/MRI enables spatial and temporal correlation not accessible by sequential or parallel methods. This is significant in neurologic and psychiatric diagnoses, where MRI is typically a firstline modality and many brain PET tracers are now available. Typical cross correlation can correct spatial and temporal changes that are due to physiological or subject motion, anatomical variability, or dynamical event transitions [47]. However, most of these methods require a relatively unobstructed view of the optical sensors from outside the scanner—which is difficult to achieve in an integrated PET/MRI scanner due to the presence of the radiofrequency coils.
For more conventional acquisition methods, motion estimates with very high temporal resolution (e.g., every 20 ms) can be obtained using embedded navigator pulses. Their use to correct PET data in very short frames are especially important for performing motion correction in the early phases of a dynamic PET study, when frames as short as 1 s are often used to sample the radiotracer AIF.
PET/fMRI
Functional magnetic resonance imaging (fMRI) evolved to capture dynamic brain events with high spatial precision. Recent combined sensing using fMRI with PET have begun to link molecular and subcellular information to functional, systems level dynamics, with the prospect of offering novel perspectives into the brain’s function and dysfunction [56]. In Parkinson’s disease, for example, simultaneous PET and MRI signaling can relate complex dopamine mechanistic responses such as the rates of release or transport (PET) with neuronal activation (fMRI) [57].
PET/Task based and resting state fMRI
Increasingly, non-invasive, task-based regimes are employed to monitor the functional consequences of perturbing the brain’s network organization, including repetitive transcranial magnetic or direct-current stimulation, that could be used to activate or inhibit select areas of the cortex, in conjunction with PET imaging [56].
From its origins in the 1990’s, resting state fMRI has evolved into a powerful and spatially accurate tool for assessing the functional organization of the brain. The early detection of resting state networks by Biswal et al. [58] used a standard 1.5 T clinical scanner equipped with a three-axis head gradient coil that obtained images every
250 ms. Under these relatively moderate scanning conditions, they showed the presence of a high degree of temporal correlation in brain activity of the sensorimotor cortex and several other regions associated with motor function in resting patients. Current procedures typically employ 3.0 T for better spatial resolution and use parallel imaging for fast data access. In special cases, high strength magnetic fields (7 T) and big data acquisition procedures are used [59]. Use of resting state fMRI has revealed, for example, that brain connectivity of the left middle frontal and pre- central gyrus, and right post central gyrus with the medial visual network is reduced in premanifest and manifest HD as compared to controls [60].
PET/MRS
Magnetic resonance spectroscopy (MRS) is a non-invasive technique used for in vivo measurement of levels of unique molecular species, such as total choline (tCho), a marker of neoplastic proliferation [61,62]. In MRS the magnetic field experienced by a particular nucleus is affected by the motions of its nearby electrons, in contrast to MRI where the magnetic moments of nuclei become oriented relative to the direction of the applied field. Hence, differently sited nuclei experience slightly different applied fields and resonate at slightly different frequencies, generating unique fingerprints for different compounds. Single-voxel MRS methods have been used to compare levels of such compounds in tumors and in adjacent or contralateral normal brain tissue in neurodegeneration.
PET/MRS combined modalities offer the prospect of simultaneous molecular assessment by two independent signal sources. The use of MRS imaging (MRSI), however, has generally been hampered by its low sensitivity in vivo. Recent developments using hyperpolarized MRS have addressed this obstacle, enabling wider use of combined
PET/MRS. With hyperpolarization signal strength can be increased by many orders of magnitude. PET/MRS studies with a combined hyperpolarized, 13C-labeled pyruvate substrate have confirmed its capability for imaging tumor metabolism [63,64].
Multiple hyperpolarization technologies have been developed for biomedical applications [65], including dissolution Dynamic Nuclear Polarization (d-DNP), Parahydrogen Induced Polarization, Signal Amplification by Reversible Exchange (SABRE), and Spin Exchange Optical Pumping. The chief objective of the hyperpolarization process is to yield sufficient hyperpolarized contrast agent (HCA) having an adequate lifetime, i.e., long T1, for in vivo distribution and metabolism. Because protons typically have low T1 values - on the order of only a few seconds - most HCA include a low-γheteronucleus (129Xe, 13C, 15N, 3He, etc.) for hyperpolarization storage and detection.
In cases where sensitivity is sufficient, various nuclear signatures can be used in PET/MRS for detection of a wide range of metabolite markers of functional integrity [66]. Use of 31P-MRS, for example, enables detection of phosphorylated metabolites, such as adenosine diphosphate (ADP), adenosine triphosphate (ATP), or phosphocreatine.
PET/MRS and radiogenomics
Radiogenomics is a novel approach to combined PET/MRS nuclear isotopic and nuclear moment modalities that interrogates large scale relationships, termed association maps, among imaging phenotypes and molecular data sets, such as those from specific gene and microRNA expression signatures. Association maps can identify high dimensional, correlation relationships, using either simple discrete measurements or complex combinatorial data, such as those between high dimensional image features and large scale molecular or genomic elements. Such relationships constitute putative biomarkers of disease, and the information has the potential for guiding treatments in the absence of new pathologic specimens [42,43].
PET/OI
PET and optical imaging (OI) dual modalities have developed chiefly in the context of surgical guidance. Optical imaging methods currently available employ a range of optical modalities [3], including fluorescent protein molecules, Cherenkov luminescence imaging, near-infrared light, and quantum dots composed from Cd/Te or Cd/Se materials. For surgical guidance, the radioactive signal enables identification and localization of a lesion by means of its radioactive signature, whereas the optical feedback allows direct visualization of the lesion in exposed tissue.
Multiprobe technologies
Dual probe scanners are chiefly an evolution of SPECT imaging, although research into multi-tracer PET has also been performed. Research on dual probe scanners has demonstrated their feasibility for radionuclides having widely separated energy profiles [9,10], based on the detection of energy differences in gamma ray emission, such as that between Tc-99m and I-123. A drawback of multi‐tracer imaging is crosstalk from other gamma rays, which affects reconstruction of the image and requires scattering correction methods to lessen background caused by energy overlap.
Due to the lack of energy difference in the measured photons, PET has traditionally relied on detection of one radio- nuclide at a time, making multiple PET scans for different radionuclides a necessity. Since multi-nuclide detection cannot be achieved via energy resolution differences, efforts to differentiate signals have explored several alternative methods including differences in half-life, staggered dose injections, and prompt gamma [67, 68]
A recent development has been that of combining PET and SPECT modalities, since these are inherently complementary [67,69]. Traditionally, this combination has been difficult to achieve due to the presence of the collimator in SPECT scanners. One proposal to overcome this difficulty is the use of Compton imaging with PET, using technology taken from astrophysical applications [69]. Absorbers, such as scintillator or semiconductor detectors, surround the subject as in PET. Additionally, there are scatterers that surround the subject inside the absorber ring. Gamma source localization is based on the coincidence between a scattered gamma ray and an absorbed gamma ray, which enables localization of the gamma source.
Enhanced signal acquisition
Important improvements in sensitivity and resolution of PET technology have included more rapidly responding and brighter scintillators that are based on materials like lutetium oxyorthosilicate (LSO), gadolinium oxyorthosilicate, and lutetium yttrium oxyorthosilicate [4,70]. Coupled with the development of solid-state read-out detectors, new scintillators now enable 3-dimensional data acquisition and use detector material composed from cadmium zinc telluride (CZT).
Small‐field planar gamma cameras
Over recent decades, small hand-held, planar gamma cameras designed for use in surgery have increased in use. Given the need for genetic therapies treatment, the smaller cameras are likely to see more frequent use in these procedures, which require targeted delivery of probe material [11]. Several groups have developed CZT-based intra-surgical systems for which a range of cameras are now commercially available. In contrast to probes, the use of cameras enables more precise viewing of a region of interest and can be combined with optical cameras for visualization.
Reconstruction software
Developments in image reconstruction continue to play an integral role in achieving optimal image quality for both SPECT and PET. In most cases iterative reconstruction [70] is used, since the contribution from attenuation, motion, and detector resolution are sufficiently large as to appreciably lessen image quality. In other case’s reconstruction can be performed more rapidly by filtered back-projection techniques.
Since all such approaches require significant computational tasking, albeit at different scales, recent proposals have advanced the concept of reconstruction free PET imaging [50]. Reconstruction free imaging is based on the hypothesis that with sufficient improvement in time-of-flight information, the need for reconstruction will be eliminated. A recent demonstration of an imaging system based on the detection of Cherenkov photons in two collimated detectors, in fact, had a coincidence TOF resolution of 32 ps3, i.e., nearly sufficient to eliminate the need for reconstruction [50].
Nuclear medicine has confirmed its place as a versatile and powerful technique for in vivo diagnosis and therapy. Recent decades have amplified these capabilities. Advances in radiochemistry, targeted delivery, and technological innovation have broadened access to domains once thought ‘undruggable’, laying the groundwork for transitioning from molecular imaging to molecular systems imaging. Radiochemical techniques are no longer limited to labeling small compounds only but now include a wide range of radio nuclides that can be attached to various large molecules with enhanced speed and simplicity. Major intracellular functions, including clearance, energetics, transport, gene transcription, and protein processing, are increasingly accessible for interrogation. Targeting has also improved, with natural and synthetic nano platforms that can be combined with radioimmunoconjugates, reporter genes, and antibody fragments. Importantly, technological developments like hybrid scanning systems are providing multimodal information sourcing that is yielding insight into tissue and cellular physiology and molecular dynamics, as well as improved spatiotemporal resolution. Time of flight determinations, moreover, are increasingly rapid, bringing reconstruction free imaging within reach.
Despite these successes, difficulties in multiplexing multiple radionuclides continue to be significant obstacles to systems molecular imaging. The inability of PET to discriminate energy levels, notably, is a major drawback to multinuclide monitoring that is only beginning to be addressed in hybrid PET/gamma counters or SPECT dual detection systems.
Molecular systems imaging promises to attain a comprehensive level of diagnostic interrogation, informing treatment decisions that are unique to individual patients. This will require the accumulation of large data sets, encompassing multiple candidates and tissue features over time and requiring large scale computational resourcing, analogous to methods currently evolving for radiogenomics. Computational and statistical resources will also need to be developed for resolving small signal differences. Protein complexes mediating key intracellular functions constitute important targets for monitoring disease states, as in the case of the huntingtin protein [8]. In many cases, the functional features of these complexes remain to be unraveled prior to the development of candidate probes. Significantly, technological developments for multiprobe monitoring are increasingly needed driving research in this key area.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina